What was known before {#section21-2054358118787480}
=====================

Prior studies found that higher dose thiazide diuretics lower urinary calcium excretion to a greater degree than lower dose thiazides. Whether or not this translates into a difference in clinical outcomes is not clear as there are no data examining the relative ability of higher vs lower dose thiazide diuretics to prevent kidney stones.

What this adds {#section22-2054358118787480}
==============

Using a large population-based administrative data set from people greater than 65 years of age we find that lower dose thiazide diuretics (⩽12.5 mg hydrochlorothiazide/chlorthalidone or ⩽1.25 mg indapamide) have a similar ability to prevent kidney stone formation as higher dose thiazides.

Introduction {#section23-2054358118787480}
============

Kidney stones are common and associate with significant morbidity and high health care costs.^[@bibr1-2054358118787480],[@bibr2-2054358118787480]^ Hypercalciuria is the most common metabolic risk factor for the development of kidney stones.^[@bibr3-2054358118787480]^ Numerous studies (including several randomized trials)^[@bibr4-2054358118787480][@bibr5-2054358118787480]-[@bibr6-2054358118787480]^ have shown the efficacy of thiazide diuretics for both lowering urinary calcium excretion and the subsequent likelihood of future kidney stone episodes.^[@bibr7-2054358118787480][@bibr8-2054358118787480]-[@bibr9-2054358118787480]^ High doses of thiazide diuretics were used in the trials (ie, ⩾50 mg of hydrochlorothiazide or ⩾ 25 mg chlorthalidone daily), and such doses are associated with a greater frequency of side effects, including electrolyte disturbance, hyperglycemia, hyperlipidemia, and glucose intolerance.^[@bibr10-2054358118787480]^ In clinical practice, lower doses are commonly employed for hypertension and also for the treatment of hypercalciuria.^[@bibr11-2054358118787480][@bibr12-2054358118787480]-[@bibr13-2054358118787480]^ However, whether lower doses of thiazides are equally as effective at preventing kidney stones is not known and a significant knowledge gap identified in guidelines from the American College of Physicians.^[@bibr8-2054358118787480]^

In this study, we determined whether initiating treatment with a low vs high dose of a thiazide diuretic is associated with an altered risk of kidney stones. We hypothesized that low doses of thiazide diuretics are as effective at preventing kidney stones as higher doses.

Methods {#section24-2054358118787480}
=======

This study employed the thiazide diuretic users from a previously generated cohort.^[@bibr9-2054358118787480]^ In that study, we described in detail the population data sources, cohort entry criteria, baseline covariates, and the identification of kidney stone events. In brief, we employed linked administrative health data to create a retrospective, population-based cohort of individuals older than 65 years of age (a segment of the Ontario population where drug coverage is a universal benefit), with a new prescription for 1 of 4 classes of antihypertensives (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers \[ACEi/ARB\], beta blockers, calcium channel blockers, and thiazide diuretics) between April 1, 2003, and March 31, 2014. The date of prescription served as the index date. We excluded patients with missing age or sex data, patients with previous antihypertensive use in the 180 days prior to index date (to ensure new use) or evidence of use of other drugs that might alter kidney stone risk (ie, furosemide, prednisone, or topiramate), patients with end-stage renal disease, and those with a hospital admission in the previous 90 days prior to index date. For the current study, we restricted to thiazide diuretic users only (hydrochlorothiazide, chlorthalidone, or indapamide), excluding patients prescribed the thiazide diuretic metolazone due to its small sample size (n = 254). A list of thiazide diuretic drug identification numbers is provided in [Supplemental Table 1](http://journals.sagepub.com/doi/suppl/10.1177/2054358118787480). We further divided thiazide diuretic users into a low-dose and a high-dose group. Individuals prescribed a low-dose thiazide diuretic were used as the referent category for all analyses. Low-dose hydrochlorothiazide was considered ⩽12.5 mg per day, low-dose chlorthalidone was considered ⩽12.5 mg per day, and low-dose indapamide was considered ⩽1.25 mg per day. The index date for our study (date where we started follow-up) was set as the date that the thiazide diuretic was prescribed. All doses higher than those detailed above were considered high dose.

We obtained vital statistics from the Registered Persons Database (RPDB). The Ontario Drug Benefit (ODB) database was used to acquire prescription drug data.^[@bibr14-2054358118787480]^ The Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) was employed to identify baseline comorbidity data, hospital admissions, and kidney stone episodes. Emergency room visits were captured with the CIHI National Ambulatory Care Reporting System (NACRS) database. Physician billing claims from the Ontario Health Insurance Plan (OHIP) as well as diagnosis and procedural codes from the CIHI-NACRS and CIHI-DAD databases were employed to identify kidney stone episodes. Other relevant episodes requiring an interaction with the health care system and some baseline comorbidities were captured in the OHIP database. The data sets were linked using unique, encoded identifiers derived from health card numbers, and patient-level data were analyzed at the Institute for Clinical Evaluative Sciences (ICES). The reporting of this and our prior study followed the guidelines for observational studies ([Supplemental Table 2](http://journals.sagepub.com/doi/suppl/10.1177/2054358118787480)).^[@bibr9-2054358118787480],[@bibr15-2054358118787480]^

Baseline covariates included age and sex, obtained from the RPDB and socioeconomic status, which was determined based on neighborhood income quintile according to Statistics Canada.^[@bibr9-2054358118787480]^ Records in the 5 years prior to the index date were used to identify baseline comorbidities including alcoholism, chronic liver disease, dementia, diabetes, heart failure, history of kidney stones, human immunodeficiency virus, hypercalcemia, hyperparathyroidism, hypertension, inflammatory bowel disease, leukemia, peripheral vascular disease, and stroke/transient ischemic attack. Three years of hospitalization records prior to the index date were used to calculate the Charlson comorbidity index, which was calculated based on the adaptation by Quan et al.^[@bibr16-2054358118787480]^ Baseline demographic, comorbidity, and treatment data were reported for each dose group according to the index thiazide diuretic prescribed.

The primary outcome was first presentation with kidney stones to a primary care physician, emergency department, or hospital following index dose of thiazide diuretic prescribed. These outcomes were captured using OHIP, CIHI-DAD, and NACRS databases, employing a validated algorithm^[@bibr17-2054358118787480][@bibr18-2054358118787480]-[@bibr19-2054358118787480]^ based on *International Classification of Diseases, Tenth Revision* (ICD-10-CA) diagnostic codes. [Supplemental Table 3](http://journals.sagepub.com/doi/suppl/10.1177/2054358118787480) lists the diagnostic codes employed to identify the outcomes.

Statistical Analysis {#section25-2054358118787480}
====================

Variables were complete with no missing values except for income quintile (0.3% missing) and rural residence (\<0.1% missing). Standardized differences were used to assess the balance in baseline variables between groups, with a standardized difference of more than 10% being considered potentially important.^[@bibr20-2054358118787480]^

Patients were followed from the time of the index thiazide diuretic prescription until the occurrence of the primary outcome, death, a prescription for a different antihypertensive (ACEi/ARB, beta blocker, calcium channel blocker), no subsequent refill prescription (stop), or the end of the study follow-up period (March 31, 2015), whichever event came first. Given the lack of an effect of other antihypertensive prescriptions on the risk of kidney stone presentation, we also repeated this analysis without censoring when another antihypertensive medication was started. A continuous user of a thiazide diuretic was defined by evidence of a repeat prescription within a period of time equivalent to 150% of the days supplied for the previous prescription.^[@bibr21-2054358118787480]^ Individuals were censored 365 days after their last prescription meeting this definition, in order to permit a formed kidney stone to become clinically apparent. Less than 0.5% of patients emigrate from the province each year, and this was a minor reason for not filling repeat prescriptions in the provincial drug database.

We used Cox proportional hazards regression with low-dose thiazide diuretics as the referent group, to estimate the hazard ratio (HR) and 95% confidence interval (CI) of a kidney stone event according to the dose of thiazide diuretic (low vs high) prescribed. Models were adjusted for the following factors, defined a priori: age (per 1 year), sex (male referent), number of primary care provider visits in the prior year (per 1 visit), location (urban referent), Charlson comorbidity score (per 1 unit increase), history of stroke, diabetes, hypertension, hypercalcemia, hyperparathyroidism, history of kidney stones, and inflammatory bowel disease. [Supplemental Table 4](http://journals.sagepub.com/doi/suppl/10.1177/2054358118787480) lists the specific codes used to identify these characteristics.

Several sensitivity analyses were performed. First, the outcome definition was restricted to a kidney stone requiring surgical intervention. We examined kidney stone risk as per the primary analysis, but without censoring for starting another antihypertensive. We examined kidney stone risk as per the primary analysis after excluding individuals receiving chlorthalidone. We examined the risk separately for those patients who remained on the same dose, compared with those who switched dose group in the first 90 days. This analysis, similar to others, examined stone events from the time of initial prescription, not from the time of switching dose. We also adjusted for a prior stone history. Consequently, for this analysis, experiencing a stone event should not influence dose adjustment. We used interaction terms to determine whether the presence or absence of a history of kidney stones in the 5 years prior to the index date, or whether the type of thiazide prescribed on the index date, modified the association between thiazide diuretic dose and the risk of kidney stones. Finally, we used an extended Cox model to assess the effect of thiazide dose, low vs high, on kidney stone events, allowing recurrent events. Kidney stone events separated by at least 45 days were considered distinct events and included in the model.

All analyses were conducted with SAS version 9.4 (SAS Institute, Cary, North Carolina, 2011) according to a prespecified protocol approved by the institutional review board at Sunnybrook Health Sciences Centre (Toronto, Ontario, Canada). Participant informed consent was not required for this study. Two-sided *P* values \<.05 were considered significant.

Results {#section26-2054358118787480}
=======

Cohort Characteristics {#section27-2054358118787480}
----------------------

We identified 105 239 persons older than the age of 65 years who started a new prescription for a thiazide diuretic. In our prior analysis, individuals prescribed a thiazide diuretic had a significantly reduced risk of having a kidney stone event relative to those prescribed another type of antihypertensive medication (adjusted hazard ratio \[HR~adj~\] = 0.77, 95% CI: 0.69-0.85, *P* \< .01).^[@bibr9-2054358118787480]^ We divided the patients receiving a thiazide diuretic into 2 groups based on total daily dose: low dose (⩽12.5 mg hydrochlorothiazide or chlorthalidone or ⩽1.25 mg indapamide; n = 49 942) and high dose (n = 55 297). Baseline characteristics were similar between groups ([Table 1](#table1-2054358118787480){ref-type="table"}; median age of 73 years, 0.8% with a kidney stone event in the last 5 years), although the high-dose group tended to be slightly younger and live in rural areas. The overall follow-up of the cohort was a median of 365 days (interquartile range \[IQR\], 248-571), which was not different between groups. The total follow-up of the cohort was 163 516 person-years.

###### 

Baseline Characteristics.

![](10.1177_2054358118787480-table1)

  Characteristics                                                                             Low dose (referent)   High dose      Standardized difference^[a](#table-fn2-2054358118787480){ref-type="table-fn"}^          
  ------------------------------------------------------------------------------------------- --------------------- -------------- -------------------------------------------------------------------------------- ------ -----
  Total patients                                                                              49°942                47.4           55°297                                                                           52.5   ---
  Demographics                                                                                                                                                                                                             
   Age at cohort entry                                                                                                                                                                                                     
   Mean ± SD                                                                                  74.55 ± 6.88          73.76 ± 6.77   12%                                                                                     
   Median (IQR)                                                                               73 (69-79)            72 (68-78)     ---                                                                                     
    66-70 years                                                                               17°818                35.7           22°676                                                                           41.0   11%
    71-75 years                                                                               12°433                24.9           13°394                                                                           24.2   2%
    76-80 years                                                                               9514                  19.1           9538                                                                             17.2   5%
    81-85 years                                                                               6214                  12.4           5933                                                                             10.7   5%
    ⩾86 years                                                                                 3963                  7.9            3756                                                                             6.8    4%
   Socioeconomic status                                                                                                                                                                                                    
    1 (poorest)                                                                               9133                  18.3           10°536                                                                           19.1   2%
    2                                                                                         10°061                20.1           11°474                                                                           20.7   1%
    3                                                                                         9548                  19.1           10°628                                                                           19.2   0%
    4                                                                                         9982                  20.0           11°005                                                                           19.9   0%
    5 (richest)                                                                               11°076                22.2           11°461                                                                           20.7   4%
    Missing                                                                                   142                   0.3            193                                                                              0.3    0%
   Sex                                                                                                                                                                                                                     
    Female                                                                                    34°699                69.5           36°809                                                                           66.6   6%
    Male                                                                                      15°243                30.5           18°488                                                                           33.4   6%
   Location^[b](#table-fn3-2054358118787480){ref-type="table-fn"}^                                                                                                                                                         
    Urban                                                                                     42°847                85.8           45°329                                                                           82.0   10%
    Rural                                                                                     7077                  14.2           9944                                                                             18.0   10%
    Missing                                                                                   18                    0.0            24                                                                               0.0    1%
   Year of cohort entry                                                                                                                                                                                                    
    2003                                                                                      5475                  11.0           6085                                                                             11.0   0%
    2004                                                                                      7795                  15.6           8703                                                                             15.7   0%
    2005                                                                                      6632                  13.3           6924                                                                             12.5   2%
    2006                                                                                      5292                  10.6           5529                                                                             10.0   2%
    2007                                                                                      4441                  8.9            4915                                                                             8.9    0%
    2008                                                                                      4038                  8.1            4257                                                                             7.7    1%
    2009                                                                                      3550                  7.1            3991                                                                             7.2    0%
    2010                                                                                      3368                  6.7            3802                                                                             6.9    1%
    2011                                                                                      3092                  6.2            3581                                                                             6.5    1%
    2012                                                                                      2980                  6.0            3618                                                                             6.5    2%
    2013                                                                                      2679                  5.4            3166                                                                             5.7    1%
    2014                                                                                      600                   1.2            726                                                                              1.3    1%
  Health care access in the past 1 year                                                                                                                                                                                    
   Primary care physician visits                                                                                                                                                                                           
    Mean ± SD                                                                                 6.49 ± 6.7            6.53 ± 7.51    1%                                                                                      
    Median (IQR)                                                                              5 (3-8)               5 (2-8)        ---                                                                                     
    0 visits                                                                                  3016                  6.0            4216                                                                             7.6    6%
    1-2 visits                                                                                8832                  17.7           10°627                                                                           19.2   4%
    ⩾3 visits                                                                                 38°094                76.3           40454                                                                            73.2   7%
   Urologist consults                                                                         3738                  7.5            4214                                                                             7.6    0%
  Comorbidities in the past 5 years                                                                                                                                                                                        
   Alcoholism                                                                                 128                   0.3            230                                                                              0.4    2%
   Chronic liver disease                                                                      1214                  2.4            1330                                                                             2.4    0%
   Dementia                                                                                   3027                  6.1            3388                                                                             6.1    0%
   Diabetes^[c](#table-fn4-2054358118787480){ref-type="table-fn"}^                            1283                  2.6            1853                                                                             3.4    5%
   Heart failure                                                                              1249                  2.5            1710                                                                             3.1    4%
   History of kidney stone^[d](#table-fn5-2054358118787480){ref-type="table-fn"}^             376                   0.8            449                                                                              0.8    0%
   HIV                                                                                        34                    0.1            33                                                                               0.1    0%
   Hypercalcemia                                                                              32                    0.1            27                                                                               0.0    4%
   Hyperparathyroidism                                                                        22                    0.0            27                                                                               0.0    4%
   Hypertension                                                                               33°790                67.7           36°867                                                                           66.7   2%
   Inflammatory bowel disease                                                                 221                   0.4            216                                                                              0.4    0%
   Leukemia                                                                                   497                   1.0            522                                                                              0.9    1%
   Peripheral vascular disease                                                                198                   0.4            251                                                                              0.5    1%
   Stroke/TIA                                                                                 436                   0.9            574                                                                              1.0    1%
   Charlson comorbidity index^[e](#table-fn6-2054358118787480){ref-type="table-fn"}^                                                                                                                                       
    Mean ± SD                                                                                 0.11 ± 0.56           0.12 ± 0.59    2%                                                                                      
    Median (IQR)                                                                              0 (0-0)               0 (0-0)        ---                                                                                     
    0                                                                                         47°305                94.7           52°055                                                                           94.1   3%
    1                                                                                         1177                  2.4            1496                                                                             2.7    2%
    2                                                                                         961                   1.9            1125                                                                             2.0    1%
    ⩾3                                                                                        499                   0.9            621                                                                              1.3    4%
   Number of unique drugs prescribed^[f](#table-fn7-2054358118787480){ref-type="table-fn"}^                                                                                                                                
    Mean ± SD                                                                                 2.92 ± 3.02           2.93 ± 3.19    0%                                                                                      
    Median (IQR)                                                                              2 (1-4)               2 (1-4)        ---                                                                                     
    \<6 drugs                                                                                 41°861                83.8           45°883                                                                           83.0   2%
    6-10 drugs                                                                                6701                  13.4           7611                                                                             13.8   1%
    11-15 drugs                                                                               1145                  2.3            1493                                                                             2.7    3%
    16-20 drugs                                                                               194                   0.4            246                                                                              0.4    0%
    21-25 drugs                                                                               33                    0.1            48                                                                               0.1    0%
    ⩾26 drugs                                                                                 8                     0.0            16                                                                               0.0    0%

*Note.* IQR = interquartile range; TIA = transient ischemic attack; DIN = drug identification number.

Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups divided by the pooled standard deviation; a value greater than 10% is interpreted as a meaningful difference between the groups.^[@bibr20-2054358118787480]^

Rural residence was defined as a population \<10 000 people.

Diabetes was considered to be use of any medication used to treat diabetes in the last 180 days preceding the index date ([Supplemental Table 4](http://journals.sagepub.com/doi/suppl/10.1177/2054358118787480)).

Documented kidney stone event in the preceding 5 years.

Charlson comorbidity index^[@bibr12-2054358118787480]^ was calculated using 3 years of hospitalization data. "No hospitalizations" received a score of 0.

Baseline medication use in the 1 year preceding the index date.

Relationship Between Dose of Thiazide Prescribed and Kidney Stone Events {#section28-2054358118787480}
------------------------------------------------------------------------

Of the 49 942 patients on a low-dose thiazide diuretic, 244 (0.49%) had a kidney stone event (2.95 events per 1000 person-years). This was very similar in the high-dose group, with 292 events (0.53%) from 55 297 persons receiving a new prescription (3.62 events per 1000 person-years). In unadjusted analyses, a high vs low dose of thiazide diuretic was associated with a higher risk of a kidney stone event (HR~unadj~ = 1.19, 95% CI: 1.01-1.41), which was attenuated after adjustment (HR~adj~ = 1.10, 95% CI: 0.93-1.31) ([Table 2](#table2-2054358118787480){ref-type="table"}). Using the more specific outcome of stone-related surgery produced similar results (HR~adj~ = 1.18, 95% CI: 0.96-1.46) ([Table 2](#table2-2054358118787480){ref-type="table"}).

###### 

Association Between Thiazide Dose and Outcomes.

![](10.1177_2054358118787480-table2)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug group                                                                                        n        n event (%)   Incidence rate per 1000 person-years   Unadjusted HR (95% CI)   Adjusted HR^[a](#table-fn9-2054358118787480){ref-type="table-fn"}^\   Adjusted *P* value
                                                                                                                                                                                           (95% CI)                                                              
  ------------------------------------------------------------------------------------------------- -------- ------------- -------------------------------------- ------------------------ --------------------------------------------------------------------- --------------------
  Primary outcome: Kidney stones                                                                                                                                                                                                                                 

   Low dose                                                                                         49°942   244 (0.49)    2.95                                   1.00 (reference)         1.00 (reference)                                                      ---

   High dose                                                                                        55°297   292 (0.53)    3.62                                   1.19\                    1.10\                                                                 .26
                                                                                                                                                                  (1.01-1.41)              (0.93-1.31)                                                           

  Secondary outcome: Kidney stone surgery                                                                                                                                                                                                                        

   Low dose                                                                                         49°942   154 (0.31)    1.86                                   1.00\                    1.00\                                                                 ---
                                                                                                                                                                  (reference)              (reference)                                                           

   High dose                                                                                        55°297   197 (0.36)    2.44                                   1.28\                    1.18\                                                                 .12
                                                                                                                                                                  (1.03-1.58)              (0.96-1.46)                                                           

  Primary outcome: Kidney stones^[b](#table-fn10-2054358118787480){ref-type="table-fn"}^                                                                                                                                                                         

   Low dose                                                                                         49°942   378 (0.76)    2.97                                   1.00\                    1.00\                                                                 ---
                                                                                                                                                                  (reference)              (reference)                                                           

   High dose                                                                                        55°297   424 (0.77)    3.35                                   1.11\                    1.03\                                                                 .70
                                                                                                                                                                  (0.96-1.27)              (0.89-1.18)                                                           

  Secondary outcome: Kidney stone surgery^[b](#table-fn10-2054358118787480){ref-type="table-fn"}^                                                                                                                                                                

   Low dose                                                                                         49 942   253 (0.51)    1.98                                   1.00\                    1.00\                                                                 ---
                                                                                                                                                                  (reference)              (reference)                                                           

   High dose                                                                                        55 297   296 (0.54)    2.34                                   1.16\                    1.08\                                                                 .36
                                                                                                                                                                  (0.98-1.37)              (0.91-1.28)                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* HR = hazard ratio; CI = confidence interval.

Models were adjusted for the following factors: age (per 1 year), sex (male referent), location (urban referent), number of primary care provider visits in the prior year (per 1 visit), Charlson comorbidity score (per 1 unit increase), history of stroke, diabetes, hypertension, hypercalcemia, hyperparathyroidism, history of kidney stones, and inflammatory bowel disease.

Repeated analysis without censoring the follow-up period for the start of a different antihypertensive.

Our previous work failed to detect an effect of other antihypertensives on the risk of developing a kidney stone.^[@bibr9-2054358118787480]^ We therefore repeated these analyses without censoring when another antihypertensive medication was prescribed ([Table 2](#table2-2054358118787480){ref-type="table"}). This longer follow-up period (median = 439 days, IQR = 365-1040) increased the proportion of individuals experiencing a kidney stone event in both groups to 378 (0.76%) in the low-dose group and to 424 (0.77%) in the high-dose group. This analysis also did not detect an altered risk in the high-dose group relative to the low-dose group (HR~adj~ = 1.03, 95% CI: 0.89-1.18, *P* = .70), including when examining for the more specific outcome of kidney stone surgery (HR~adj~ = 1.08, 95% CI: 0.91-1.28, *P* = .36). These data are consistent with lower dose thiazide diuretics conferring a similar effect to high-dose thiazide diuretics on the rate of presenting with a kidney stone event.

Sensitivity Analyses {#section29-2054358118787480}
--------------------

To evaluate the potential effect of switching from a low- to a high-dose thiazide diuretic thereby biasing our results, we examined the risk of having a kidney stone in those that remained on either low or high dose and in those that switched to a different dose group within 90 days of initial prescription ([Table 3](#table3-2054358118787480){ref-type="table"}). This analysis demonstrated an increased risk in the small number of patients (n = 1693), who started the study on a high dose then switched to a low-dose relative to those who remained on the low-dose throughout (HR~adj~ = 2.19, 95% CI: 1.28-3.78, *P* = .005). Interestingly, those who remained on the high dose did not have an increased risk of presenting with a kidney stone (HR~adj~ = 1.11, 95% CI: 0.92-1.33), nor did the patients whose dose escalated from low to high dose (HR~adj~ = 1.19, 95% CI: 0.86-1.64) relative to those who continued a low-dose thiazide diuretic.

###### 

Sensitivity Analysis, Examining the Primary Outcome by Dose Switch.

![](10.1177_2054358118787480-table3)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dose switches                n        n event (%)   Incidence rate per 1000 person-years   Unadjusted HR (95% CI)   Adjusted HR^[a](#table-fn12-2054358118787480){ref-type="table-fn"}^\   Adjusted *P* value
                                                                                                                      (95% CI)                                                               
  ---------------------------- -------- ------------- -------------------------------------- ------------------------ ---------------------------------------------------------------------- --------------------
  Low to low dose (referent)   41°776   199\          2.87                                   1.00\                    1.00\                                                                  ---
                                        (0.48)                                               (reference)              (reference)                                                            

  Low to high dose             8166     45\           3.30                                   1.18\                    1.19\                                                                  .30
                                        (0.55)                                               (0.85-1.63)              (0.86-1.64)                                                            

  High to low dose             1693     14\           6.39                                   2.12\                    2.19\                                                                  .005
                                        (0.83)                                               (1.23-3.64)              (1.28-3.78)                                                            

  High to high dose            53°604   278\          3.54                                   1.20\                    1.11\                                                                  .27
                                        (0.52)                                               (1.00-1.44)              (0.92-1.33)                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* HR = hazard ratio; CI = confidence interval.

Models were adjusted for the following factors: age (per 1 year), sex (male referent), location (urban referent), number of primary care provider visits in the prior year (per 1 visit), Charlson comorbidity score (per 1 unit increase), history of stroke, diabetes, hypertension, hypercalcemia, hyperparathyroidism, history of kidney stones, and inflammatory bowel disease.

To avoid the potentially confounding effect of different thiazide diuretics, we repeated the analysis after excluding patients receiving chlorthalidone. This did not alter the primary outcome. Persons on a higher dose thiazide diuretic had a similar risk of kidney stones (HR~adj~ = 1.12, 95% CI: 0.94-1.33, p = 0.21). We also examined whether our primary analysis was modified by history of prior kidney stone and did not find an effect modification ([Table 4](#table4-2054358118787480){ref-type="table"}, *P* = .42). Persons with a history of a kidney stone in the prior 5 years had similar risk of recurrence (HR~adj~ = 1.26, 95% CI: 0.74-2.13). We also assessed whether thiazide diuretic type modified our results. For patients treated with either hydrochlorothiazide or indapamide, the risk of developing a kidney stone event by dose of drug was unaltered by specific thiazide type. Finally, we examined the effect of thiazide dose on the risk of kidney stones, allowing multiple events per individual ([Table 5](#table5-2054358118787480){ref-type="table"}). This increased the total number of events to 654. High-dose thiazide, relative to low-dose thiazide, was not associated with kidney stones, even when allowing multiple kidney stone events (HR~adj~ = 1.11, 95% CI: 0.95-1.30).

###### 

Subgroup Analysis.

![](10.1177_2054358118787480-table4)

  --------------------------------------------------------------------------------------------------------------------------------------------
  Drug group             n        n event (%)   Adjusted RR^[a](#table-fn14-2054358118787480){ref-type="table-fn"}^\   Interaction *P* value
                                                (95% CI)                                                               
  ---------------------- -------- ------------- ---------------------------------------------------------------------- -----------------------
  Prior stones                                                                                                         

   Low dose (referent)   376      23 (6.12)     1.00\                                                                  .42
                                                (reference)                                                            

   High dose             449      40 (8.91)     1.26 (0.74-2.13)                                                       

  No prior stones                                                                                                      

   Low dose (referent)   49°566   221 (0.45%)   1.00\                                                                  
                                                (reference)                                                            

   High dose             54°848   252 (0.46%)   1.08 (0.90-1.30)                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------

*Note.* RR = relative risk; CI = confidence interval.

Models were adjusted for the following factors: age (per 1 year), sex (male referent), location (urban referent), number of primary care provider visits in the prior year (per 1 visit), Charlson comorbidity score (per 1 unit increase), history of stroke, diabetes, hypertension, hypercalcemia, hyperparathyroidism, history of kidney stones, and inflammatory bowel disease.

###### 

Recurrent Event Analysis.

![](10.1177_2054358118787480-table5)

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Drug group   n        n persons with an event (%)   Total number of events   Unadjusted HR (95% CI)   Adjusted HR^a^\    Adjusted *P* value
                                                                                                        (95% CI)           
  ------------ -------- ----------------------------- ------------------------ ------------------------ ------------------ --------------------
  Low dose     49°942   244 (0.49)                    298                      1.00 (reference)         1.00 (reference)   ---

  High dose    55°297   292 (0.53)                    356                      1.22 (1.05-1.43)         1.11 (0.95-1.30)   .19
  ---------------------------------------------------------------------------------------------------------------------------------------------

*Note.* HR = hazard ratio; CI = confidence interval. Models were adjusted for the following factors: age (per 1 year), sex (male referent), location (urban referent), number of primary care provider visits in the prior year (per 1 visit), Charlson comorbidity score (per 1 unit increase), history of stroke, diabetes, hypertension, hypercalcemia, hyperparathyroidism, history of kidney stones, and inflammatory bowel disease.

Discussion {#section30-2054358118787480}
==========

In a large population of persons receiving a new prescription for a thiazide diuretic, we found that lower dose thiazide diuretics confers a statistically similar protective effect compared with higher dose diuretics. Our results were robust to the more specific definition of requiring kidney stone surgery and were not modified by having a history of prior kidney stones. This work provides support for using lower dose thiazide diuretics to prevent recurrent kidney stone episodes.

Our inability to find an effect of thiazide dose on kidney stone risk could be explained by the fact that thiazide diuretics reduce kidney stone risk independently of their urinary calcium lowering effect or that thiazides have a similar ability to reduce calciuria at a range of doses. However, the limited evidence available supports that higher doses of hydrochlorothiazide have a greater urinary calcium lowering effect.^[@bibr13-2054358118787480],[@bibr22-2054358118787480]^ The nature of our cohort is such that we do not have information about urinary calcium excretion or the influence of thiazide dose on calciuria. However, in several trials examining the protective effect of thiazide diuretics, a protective effect was demonstrated even though hypercalciuria was not an inclusion criterion.^[@bibr5-2054358118787480],[@bibr23-2054358118787480],[@bibr24-2054358118787480]^ Consistent with this, we did not find an effect modification by history of kidney stones in our current or prior analysis (albeit the confidence intervals were wide), consistent with thiazide diuretics being protective regardless of the presence of this metabolic abnormality.^[@bibr9-2054358118787480]^

The median follow-up of our cohort was 365 days. This is a relatively short time as it may take considerably longer for a kidney stone to form and become clinically apparent. Nonetheless, in a prior study employing this cohort we demonstrated a clear reduction in the risk of forming a kidney stone when an individual was prescribed a thiazide diuretic in comparison to another antihypertensive.^[@bibr9-2054358118787480]^ This is consistent with the possibility that thiazide diuretics might have another effect on kidney stone formation/presentation, such as stabilizing calculi in situ, lowering urinary oxalate excretion or urinary pH, independent of lowering urinary calcium excretion.^[@bibr25-2054358118787480],[@bibr26-2054358118787480]^

A recent meta-analysis by Fink et al clearly highlights the utility of thiazide diuretics in preventing further kidney stone events in persons with a history of kidney stones.^[@bibr8-2054358118787480]^ The trials included in this review were completed in the 1980s and early 1990s when much higher doses of thiazide diuretics were utilized than are currently employed in clinical practice for the treatment of hypertension.^[@bibr23-2054358118787480],[@bibr24-2054358118787480],[@bibr27-2054358118787480]^ Higher doses of thiazide diuretics can lead to side effects such as hyperglycemia, hyperlipidemia, and glucose intolerance, which may increase the risk of cardiovascular disease.^[@bibr28-2054358118787480]^ Thus, for the treatment of hypertension, practitioners have used progressively lower doses. Fortunately, lower doses have a similar effect on reducing blood pressure and cardiovascular risk.^[@bibr29-2054358118787480]^ One study suggests that practitioners have adopted these lower doses for the prevention of kidney stones without any evidence that they remain effective for the prevention of recurrent kidney stone episodes.^[@bibr13-2054358118787480]^ Consequently, there is currently a clinical trial examining this.^[@bibr30-2054358118787480]^ We provide evidence that lower dose thiazide diuretics confer a similar protective effect to high-dose thiazide diuretics on the risk of having a kidney stone episode.

Despite employing a large cohort of patients prescribed a new thiazide diuretic, this work has limitations. Our outcome required the person to seek medical care for a kidney stone, and therefore we could not detect asymptomatic kidney stones or events for which an individual did not seek medical attention. This also prevented us from determining whether an event was due to a single stone or multiple and whether a recurrent event was due to a prior or new kidney stone. Although we adjusted for several confounders, including important comorbidities, we were unable to adjust for other potential confounders altering kidney stone formation risk, such as dietary factors. Furthermore, individuals were not randomly assigned a thiazide diuretic dose. Consequently, there is a risk of residual confounding. Our follow-up period was short; nonetheless, this time frame was sufficient to detect a difference in risk of stone presentation between different classes of antihypertensives.^[@bibr9-2054358118787480]^ Finally, our cohort only included individuals older than 65 years of age, and whether or not our results are valid in a younger population needs to be confirmed.

Conclusions {#section31-2054358118787480}
===========

We employed a large cohort of individuals receiving a new prescription for a thiazide diuretic to examine the relative risk of presenting with a kidney stone based on the dose (low vs high) of drug prescribed. We showed no difference in the likelihood of an event in those prescribed low- vs high-dose thiazide diuretics. These results are consistent with lower dose thiazide diuretics preventing kidney stones to the same degree as higher doses.
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